Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
  1. Home
  3. Nrs2002 Score As A Prognostic Factor In Solid Tumors Treated With Immune Checkpoint Inhibitor Therapy: A Real-world Evidence Analysis.
  1. Home
  3. Nrs2002 Score As A Prognostic Factor In Solid Tumors Treated With Immune Checkpoint Inhibitor Therapy: A Real-world Evidence Analysis.

Related Experiment Video

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world

Wanfen Tang1, Chenghui Li1, Dong Huang2

  • 1Department of Medical Oncology, Jinhua Municipal Central Hospital, Hangzhou, China.

Cancer Biology & Therapy
|May 30, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Nutritional risk, assessed by the NRS2002 score, significantly impacts cancer immunotherapy outcomes. Patients without nutritional risk show better progression-free survival and overall survival with immune checkpoint inhibitor treatment.

Keywords:
Nutritional Risk Screening (NRS) 2002Tumor immune checkpoint inhibitor therapycancer nutritionreal-world research

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Related Experiment Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Area of Science:

  • Oncology
  • Immunotherapy
  • Nutritional Science

Background:

  • Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer treatment.
  • Real-world data is crucial for understanding ICI efficacy beyond clinical trials.
  • Nutritional status is increasingly recognized as a factor influencing cancer patient outcomes.

Purpose of the Study:

  • To evaluate the real-world antitumour efficacy of programmed death 1 (PD-1) inhibitors.
  • To explore the association between the NRS2002 score and other clinical factors with ICI treatment efficacy.
  • To determine the prognostic value of the NRS2002 score in patients receiving immunotherapy.

Main Methods:

  • Retrospective analysis of 341 solid tumor patients treated with ICIs between June 2018 and December 2021.
  • Documentation of patient characteristics, ICI responses, and survival status.
  • Statistical analysis including univariate analysis and Cox regression to identify prognostic factors.

    • Main Results:

    • Median progression-free survival (PFS) was 5.8 months and median overall survival (OS) was 12.5 months.
    • NRS2002 score, Performance Status (PS), Naples Prognostic Score (NPS), LCR, line of therapy, and nutritional support were associated with PFS or OS.
    • Patients without nutritional risk (NRS2002 0-2) had significantly better PFS and OS compared to those with nutritional risk (NRS2002 ≥ 3).
    • The NRS2002 score was an independent prognostic factor for both PFS and OS.
    • Objective response rate (ORR) was lower in patients with nutritional risk (8.33%) versus without (19.71%).

    Conclusions:

    • Patients with nutritional risk, as indicated by the NRS2002 score, experience poorer prognosis during ICI therapy.
    • The NRS2002 score can serve as a preliminary index for predicting the efficacy of immune checkpoint inhibitor therapy.
    • Addressing nutritional status may be important for optimizing outcomes in patients undergoing immunotherapy.